For laboratory research use only — not for human consumption
For laboratory research use only — not for human consumption
Comparison
A neutral, structural comparison of MOTS-c and Retatrutide as research compounds — written for researchers evaluating the two. It describes structure and research context only; it makes no human-use, dosing, or therapeutic claim. Both are supplied for in-vitro laboratory research use only.
| MOTS-c | Retatrutide | |
|---|---|---|
| Class | Mitochondrial-derived peptide | Triple-agonist peptide (GLP-1 / GIP / glucagon) |
| Research area | Mitochondrial-peptide research | Metabolic & receptor-signalling research |
| CAS number | 1627580-64-6 | 2381089-83-2 |
| Molecular formula | C101H152N28O22S2 | C221H342N46O68 |
| Sequence | Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg | — |
| HPLC purity | 99% | 99.66% |
MOTS-c is a mitochondrial-derived peptide (encoded within the mitochondrial genome) studied in laboratory research into mitochondrial and metabolic-signalling pathways. As one of the better-characterised mitochondrial-derived peptides, it is a frequent reference compound in this emerging research area.
Retatrutide is a synthetic triple-agonist peptide investigated in laboratory research into metabolic and receptor-signalling pathways. It is studied for its simultaneous activity across the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptor systems — the reason it appears frequently in comparative metabolic-research literature alongside single-agonist (GLP-1) and dual-agonist (GLP-1/GIP) reference peptides.
Both compounds are supplied strictly for in-vitro laboratory research use only. Not for human or veterinary use. This comparison is structural and contextual and does not constitute advice on use.
